公开(公告)号：US20220054527A1

公开(公告)日：2022-02-24

申请号：US17518415

申请日：2021-11-03

申请人： Ethicon, Inc. ,  Omrix Biopharmaceuticals Ltd.

发明人： James Galloway ,  Tamara BYK-TENNENBAUM ,  Erez ILAN ,  Lior WEISSMAN ,  Sivan DORON ,  Eve MONTIA ,  Niels-Derrek Schmitz

IPC分类号： A61K31/717 ,  A61K31/704 ,  A61L24/00 ,  A61L15/28 ,  A61L24/08 ,  A61L15/44

摘要： Provided are implants and a glycolytic dependent compound for use in enhancing toxicity of the glycolytic dependent compound towards a cell, tissue and/or organ e.g., a diseased cell, tissue and/or organ, wherein the implant and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.

公开(公告)号：US20210154224A1

公开(公告)日：2021-05-27

申请号：US17167428

申请日：2021-02-04

申请人： Ethicon, Inc. ,  Omrix Biopharmaceuticals Ltd.

发明人： James Galloway ,  Tamara BYK-TENNENBAUM ,  Erez ILAN ,  Lior WEISSMAN ,  Sivan DORON ,  Eve MONTIA

IPC分类号： A61K31/717 ,  A61K31/704 ,  A61L24/00 ,  A61L15/28 ,  A61L24/08 ,  A61L15/44

摘要： Provided is a method of enhancing toxicity of a glycolytic dependent compound towards a cell, tissue and/or organ e.g. a diseased cell, tissue and/or organ, the method comprises contacting Oxidized Regenerated Cellulose (ORC) and/or Oxidized Cellulose (OC); and a glycolytic dependent compound with the cell, tissue and/or organ. The ORC and/or OC; and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.